Table S26. Association of clinical characteristics of benralizumab-treated patients with improvement in lung function.

| Characteristics | N | Response | | $X^2$ | p-value | Ref. Cat | OR | CI 95% |
|---|---|---|---|---|---|---|---|---|
| | | R N (%) | NR N (%) | | | | | |
| Sex | | | | | | | | |
| Female | 34 | 25 (73.5) | 9 (26.5) | 0.0492 | 0.824 | | | |
| Male | 17 | 12 (70.6) | 5 (29.4) | | | | | |
| Age of initiation BT (years) | 51 | 37 (72.5) | 14 (27.5) | | 0.244 | | | |
| Years with asthma | 51 | 37 (72.5) | 14 (27.5) | | 0.675 | | | |
| BMI (kg/m2) | | | | | | | | |
| <25 | 9 | 7 (77.8) | 2 (22.2) | 0.15 | 0.699 | | | |
| >25 | 42 | 30 (71.4) | 12 (28.6) | | | | | |
| Previous respiratory disease | | | | | | | | |
| Yes | 24 | 17 (70.8) | 7 (29.2) | 0.067 | 0.796 | | | |
| No | 27 | 20 (74.1) | 7 (25.9) | | | | | |
| Tobacco consumption | | | | | | | | |
| Non-smoker | 39 | 30 (76.9) | 9 (23.1) | | 0.091* | | | |
| Current smoker | 2 | 0 (0) | 2 (100) | | | | | |
| Former smoker | 10 | 7 (70) | 3 (30) | | | | | |
| Polyps | | | | | | | | |
| Yes | 20 | 18 (90) | 2 (10) | 5.0314 | 0.025 | No | 5.68 | 1.31-39.9 |
| No | 31 | 19 (61.3) | 12 (38.7) | | | | | |
| Allergies | | | | | | | | |
| Yes | 33 | 24 (72.7) | 9 (27.3) | 0.0015 | 0.969 | | | |
| No | 18 | 13 (72.2) | 5 (27.8) | | | | | |
| GERD | | | | | | | | |
| Yes | 22 | 18 (81.8) | 4 (18.2) | 1.6691 | 0.196 | | | |
| No | 29 | 19 (65.5) | 10 (34.5) | | | | | |
| SAHS | | | | | | | | |
| Yes | 10 | 7 (70) | 3 (30) | 0.0406 | 0.84 | | | |
| No | 41 | 30 (73.2) | 11 (26.8) | | | | | |
| COPD | | | | | | | | |
| Yes | 10 | 7 (70) | 3 (30) | 0.0406 | 0.84 | | | |
| No | 41 | 30 (73.2) | 11 (26.8) | | | | | |
| Age of diagnosis (years) | 51 | 37 (72.5) | 14 (27.5) | | 0.295 | | | |
| <18 | 1 | 0 (0) | 1 (100) | | 0.275* | | | |
| >18 | 50 | 37 (74) | 13 (26) | | | | | |
| ICS (µg/day) | 51 | 37 (72.5) | 14 (27.5) | | 0.461 | | | |
| OCS cycles per year | | | | | | | | |
| Yes | 45 | 33 (73.3) | 12 (26.7) | | 0.661* | | | |
| No | 6 | 4 (66.7) | 2 (33.3) | | | | | |
| Baseline FEV1 (%) | | | | | | | | |
| <80 | 34 | 22 (64.7) | 12 (35.3) | 3.1506 | 0.076 | <80 | 4.09 | 0.94-28.78 |
| >80 | 17 | 15 (88.2) | 2 (11.8) | | | | | |
| Exacerbation in previous year | | | | | | | | |
| Yes | 22 | 13 (59.1) | 9 (40.9) | 3.5186 | 0.061 | Yes | 3.32 | 0.95-12.85 |
| No | 29 | 24 (82.8) | 5 (17.2) | | | | | |
| Basal blood eosinophils (cell/mcl) | | | | | | | | |
| <300 | 47 | 34 (72.3) | 13 (27.7) | 0.0131 | 0.909 | | | |
| >300 | 4 | 3 (75) | 1 (25) | | | | | |
| Previous BT | | | | | | | | |
| Yes | 20 | 14 (70) | 6 (30) | 0.1074 | 0743 | | | |
| No | 31 | 23 (74.2) | 8 (25.8) | | | | | |

BMI, body mass index; GERD, gastroesophageal reflux disease; SAHS, sleep apnea-hypopnea syndrome; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; OCS, oral corticosteroids; FEV1, maximum expiratory volume in the first second of forced expiration; BT, biological therapy.
Ref. Cat, Reference category; NR, Non-Responder; R, Responder; OR, Odds Ratio; CI 95%, Confidence interval; *p-value for Fisher's Exact Test.